9 January 2023 - The US Supreme Court on Monday turned away Pfizer's bid to revive its plan to cover out of pocket expenses of Medicare patients for drugs costing $225,000 a year to treat a rare heart condition after federal officials found that the drugmaker's arrangement could amount to illegal kickbacks.

The justices took up Pfizer's appeal of a lower court's ruling that agreed with the Government's view that the company's proposal to directly cover cost-sharing co-payments required of patients to use its Vyndaqel and Vyndamax drugs could violate a federal law called the Anti-Kickback Statute.

Read Reuters article